Sheng‐Yu Ku

4.3k total citations · 1 hit paper
35 papers, 1.8k citations indexed

About

Sheng‐Yu Ku is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Sheng‐Yu Ku has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 17 papers in Molecular Biology and 11 papers in Cancer Research. Recurrent topics in Sheng‐Yu Ku's work include Prostate Cancer Treatment and Research (22 papers), Epigenetics and DNA Methylation (8 papers) and Cancer Genomics and Diagnostics (6 papers). Sheng‐Yu Ku is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Epigenetics and DNA Methylation (8 papers) and Cancer Genomics and Diagnostics (6 papers). Sheng‐Yu Ku collaborates with scholars based in United States, Italy and Canada. Sheng‐Yu Ku's co-authors include Himisha Beltran, Leigh Ellis, Martin Gleave, David W. Goodrich, Henry W. Long, Роберто Пили, Myles Brown, Spencer R. Rosario, Eduardo Cortes Gomez and Massimo Loda and has published in prestigious journals such as Science, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Sheng‐Yu Ku

34 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

2017 680 citations Sheng‐Yu Ku, Spencer R. Rosario et al. Science profile →

Peers

Countries citing papers authored by Sheng‐Yu Ku

Since Specialization

Citations

This map shows the geographic impact of Sheng‐Yu Ku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng‐Yu Ku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng‐Yu Ku more than expected).

Fields of papers citing papers by Sheng‐Yu Ku

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheng‐Yu Ku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng‐Yu Ku. The network helps show where Sheng‐Yu Ku may publish in the future.

Co-authorship network of co-authors of Sheng‐Yu Ku

This figure shows the co-authorship network connecting the top 25 collaborators of Sheng‐Yu Ku. A scholar is included among the top collaborators of Sheng‐Yu Ku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheng‐Yu Ku. Sheng‐Yu Ku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy 2025 ·JCI Insight ·Keisuke Shigeta, (unknown), Hiroshi Hongo, Sheng‐Yu Ku, Hiroki Ozawa, Naoki Haratake, Atsushi Fushimi, (unknown), Atrayee Bhattacharya, Shinkichi Takamori, (unknown), (unknown), (unknown), Takeo Kosaka, (unknown), (unknown), Mark D. Long, Himisha Beltran, Donald Küfe	1
2	Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer 2025 ·Molecular Cancer Therapeutics ·Sheng‐Yu Ku, (unknown), (unknown), (unknown), David J. Einstein, Steven P. Balk, Yasutaka Yamada, Himisha Beltran	0
3	Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer 2024 ·Journal of Clinical Investigation ·Sheng‐Yu Ku, (unknown), (unknown), Yasutaka Yamada, Kei Mizuno, Mark D. Long, Spencer R. Rosario, Meenalakshmi Chinnam, (unknown), Loredana Puca, Min Jin Kim, Martin Bakht, Varadha Balaji Venkadakrishnan, Brian D. Robinson, Andrés Acosta, Kristine M. Wadosky, Juan Miguel Mosquera, David W. Goodrich, Himisha Beltran	16
4	Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial 2023 ·JNCI Journal of the National Cancer Institute ·Takayuki Sumiyoshi, Xiaofei Wang, Evan W. Warner, Andrea Sboner, Matti Annala, Michael Sigouros, Kevin Beja, Kei Mizuno, Sheng‐Yu Ku, Ladan Fazli, James A. Eastham, Mary‐Ellen Taplin, Jeffrey P. Simko, Susan Halabi, Michael J. Morris, Martin Gleave, Alexander W. Wyatt, Himisha Beltran	2
5	PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression 2023 ·Oncogene ·(unknown), (unknown), Yanqing Wang, Joseph R. Cohen, Sheng‐Yu Ku, David W. Goodrich, Irwin H. Gelman	14
6	Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer 2023 ·Nature Cancer ·Martin Bakht, Yasutaka Yamada, Sheng‐Yu Ku, Varadha Balaji Venkadakrishnan, (unknown), Teja Kalidindi, Kei Mizuno, Shin Hye Ahn, Ji-Heui Seo, (unknown), Francesca Khani, Olivier Elemento, Henry W. Long, (unknown), Nagavarakishore Pillarsetty, Jason S. Lewis, Matthew L. Freedman, Anthony P. Belanger, Quang‐Dé Nguyen, Himisha Beltran	58
7	Abstract PR008: Molecular determinants of prostate cancer lineage plasticity 2023 ·Cancer Research ·Kristine M. Wadosky, Sheng‐Yu Ku, Yanqing Wang, Xiaojing Zhang, Jie Wang, Jianmin Wang, Himisha Beltran, David W. Goodrich	1
8	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis 2021 ·npj Precision Oncology ·Vincenza Conteduca, Sheng‐Yu Ku, (unknown), (unknown), Jerry Lee, Adam Jendrisak, (unknown), (unknown), (unknown), Michael Sigouros, (unknown), Ryan Dittamore, (unknown), Juan Miguel Mosquera, Joseph D. Schonhoft, Himisha Beltran	22
9	Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer 2021 ·Cancer Research ·Kenji Unno, Zachary R. Chalmers, Sahithi Pamarthy, Rajita Vatapalli, Yara Rodríguez, Barbara Lysy, Hanlin Mok, Vinay Sagar, Huiying Han, Young A. Yoo, Sheng‐Yu Ku, Himisha Beltran, Yue Zhao, Sarki A. Abdulkadir	41
10	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer 2020 ·Journal of Clinical Investigation ·Himisha Beltran, Alessandro Romanel, Vincenza Conteduca, Nicola Casiraghi, Michael Sigouros, Gian Marco Franceschini, Francesco Orlando, Tarcisio Fedrizzi, Sheng‐Yu Ku, Emma Dann, Alicia Alonso, Juan Miguel Mosquera, Andrea Sboner, Jenny Xiang, Olivier Elemento, David M. Nanus, Scott T. Tagawa, Matteo Benelli, Francesca Demichelis	132
11	Genomic and clinical characterization of stromal infiltration markers in prostate cancer 2020 ·Cancer ·Brandon A. Mahal, Mohammed Alshalalfa, Shuang G. Zhao, Himisha Beltran, William S. Chen, Fallon Chipidza, Elai Davicioni, R. Jeffrey Karnes, Sheng‐Yu Ku, Tamara L. Lotan, Vinayak Muralidhar, Timothy R. Rebbeck, Edward M. Schaeffer, Daniel E. Spratt, Felix Y. Feng, Paul L. Nguyen	9
12	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy 2020 ·Molecular Cancer Therapeutics ·Vincenza Conteduca, Sheng‐Yu Ku, Loredana Puca, (unknown), (unknown), Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa, Himisha Beltran	46
13	Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma 2019 ·Molecular Cancer Therapeutics ·May Elbanna, Ashley Orillion, Nur P. Damayanti, Remi Adelaiye‐Ogala, Li Shen, Kiersten Marie Miles, Sreenivasulu Chintala, Eric Ciamporcero, Swathi Ramakrishnan, Sheng‐Yu Ku, Karen Rex, Sean Caenepeel, Angela Coxon, Роберто Пили	10
14	Towards precision oncology in advanced prostate cancer 2019 ·Nature Reviews Urology ·Sheng‐Yu Ku, Martin Gleave, Himisha Beltran	163
15	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma 2018 ·Clinical Cancer Research ·Nur P. Damayanti, Justin A. Budka, Heba Khella, Mary W. Ferris, Sheng‐Yu Ku, Eric Kauffman, (unknown), (unknown), (unknown), Remi Adelaiye‐Ogala, May Elbanna, Ashley Orillion, Sreenivasulu Chintala, Chinghai Kao, W. Marston Linehan, George M. Yousef, Peter C. Hollenhorst, Роберто Пили	61
16	Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance breakdown → 2017 ·Science ·Sheng‐Yu Ku, Spencer R. Rosario, Yanqing Wang, Ping Mu, Mukund Seshadri, (unknown), (unknown), David P. Labbé, Eduardo Cortes Gomez, Jianmin Wang, Henry W. Long, Bo Xu, Myles Brown, Massimo Loda, Charles L. Sawyers, Leigh Ellis, David W. Goodrich	680
17	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage 2015 ·Oncogene ·Eric Ciamporcero, He Shen, Swathi Ramakrishnan, Sheng‐Yu Ku, Sreenivasulu Chintala, Li Shen, (unknown), Kiersten Marie Miles, Chiara Ullio, Stefania Pizzimenti, Martina Daga, Gissou Azabdaftari, Kristopher Attwood, Candace S. Johnson, (unknown), Giuseppina Barrera, Роберто Пили	108
18	Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications 2014 ·Molecular Cancer Therapeutics ·Remi Adelaiye‐Ogala, Eric Ciamporcero, Kiersten Marie Miles, Paula Sotomayor, Jonathan Bard, Maria Tsompana, (unknown), Li Shen, Swathi Ramakrishnan, Sheng‐Yu Ku, Ashley Orillion, Joshua Prey, Gerald J. Fetterly, Michael Buck, Sreenivasulu Chintala, Georg A. Bjarnason, Роберто Пили	56
19	CFS-1686 Causes Cell Cycle Arrest at Intra-S Phase by Interference of Interaction of Topoisomerase 1 with DNA 2014 ·PLoS ONE ·(unknown), Chia-Ning Yang, Sheng‐Yu Ku, (unknown), (unknown), (unknown), Hsin-Wen Chang, Chun‐Mao Lin, Jaulang Hwang, Yeh-Long Chen, (unknown), Chihuei Wang	12
20	Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer 2013 ·Oncotarget ·Leigh Ellis, Sheng‐Yu Ku, Swathi Ramakrishnan, Elena Lasorsa, (unknown), Alejandro Godoy, Роберто Пили	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact